跳至主要内容
临床试验/NCT00244465
NCT00244465已完成不适用

Post Marketing Non-interventional Surveillance Pharmacoepidemiology Study (PMSS) to Evaluate Long-term Safety, Tolerability and Compliance in Administration of Xyrem® (Sodium Oxybate) Oral Solution in Patients Who Receive Treatment With This Medication in Regular Clinical Practice.

UCB Pharma41 个研究点 分布在 9 个国家目标入组 750 人开始时间: 2006年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
UCB Pharma
入组人数
750
试验地点
41
主要终点
Evaluation of risk for development adverse events, withdrawal syndrome and potential for dependence, abuse, overdose and misuse of Xyrem®. Obtaining information about adherence to Xyrem® prescribing information regarding indication and dosage.

研究概览

简要总结

Patients will be followed up for max 18 months. Information on the Adverse Events and potential misuse or abuse of Xyrem ® will be collected.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients who received Xyrem ® on prescription

排除标准

  • No limitations

结局指标

主要结局

Evaluation of risk for development adverse events, withdrawal syndrome and potential for dependence, abuse, overdose and misuse of Xyrem®. Obtaining information about adherence to Xyrem® prescribing information regarding indication and dosage.

时间窗: 12 months

次要结局

未报告次要终点

研究者

发起方
UCB Pharma
申办方类型
Industry
责任方
Sponsor

研究点 (41)

Loading locations...

相似试验

Observational Study to Evaluate Risks of Side... | 临床试验